I have to agree with oldcogger, CDiddy. The proto
Post# of 153903
(Total Views: 779)
Posted On: 08/06/2020 6:14:35 PM
I have to agree with oldcogger, CDiddy. The protocol is 395 with a 2-1 ratio. We can go at 195 which IMO is the right time to unblind. Just remember, the FDA can still say at 170-180 is not quite enough or come up with some other reason to not go along with that many fewer.
I get your point CDiddy, 15 or so is not alot but with the way the FDA operates and Fauci and his cronies, you never know what power they could use to hinder us by saying it's not enough, continue the trial. I don't know about you or any of the other investors here on this Hangout MB but I don't want to give those above an inch to shoot CYDY down over 15 or so less than the 195 patients.
Just look at all the other therapy's out there like the one mentioned this morning Replive?? (not sure of name) that climbed from .29 to over .62 on a lot of volume just because they're getting more attention than us.
Finally, I say let them over even enroll past 195 if it gets us more for statistical analysis and proves, once and for all that Leronlimab is so much better with 3 MOA's where the other therapy's don't really have all 3 MOA's like Leronlimab has and even a 4th, but I could be wrong. Maybe the 4th MOA is the longhaulers.
End of my rant and opinion.
GLTA
HCIT
I get your point CDiddy, 15 or so is not alot but with the way the FDA operates and Fauci and his cronies, you never know what power they could use to hinder us by saying it's not enough, continue the trial. I don't know about you or any of the other investors here on this Hangout MB but I don't want to give those above an inch to shoot CYDY down over 15 or so less than the 195 patients.
Just look at all the other therapy's out there like the one mentioned this morning Replive?? (not sure of name) that climbed from .29 to over .62 on a lot of volume just because they're getting more attention than us.
Finally, I say let them over even enroll past 195 if it gets us more for statistical analysis and proves, once and for all that Leronlimab is so much better with 3 MOA's where the other therapy's don't really have all 3 MOA's like Leronlimab has and even a 4th, but I could be wrong. Maybe the 4th MOA is the longhaulers.
End of my rant and opinion.
GLTA
HCIT
(2)
(0)